In addition, our data revealed that ATL III treatment restored hepatic expression of AdipoR1 that was markedly down-regulated in the HFD-induced NAFLD mouse model and FFAs-treated HepG2 cell model. This evidence concerns the gene ADIPOR1 and metabolic dysfunction-associated steatotic liver disease.